How Smarteeva Enables Proactive Post-Market Surveillance with Real-World Data

How Smarteeva Enables Proactive Post-Market Surveillance with Real-World Data

The medical device industry has spent the last decade producing post-market surveillance data faster than most quality teams can read it. Complaint volumes are up. Real-world data sources are multiplying.

Regulatory expectations have tightened across FDA, EU MDR, and the Asian regulators. The teams that are pulling ahead share one trait.

They treat post-market surveillance as a proactive function that catches signals before they become recalls. Reactive surveillance responds after the regulator asks a question. The shift between the two changes how quality teams operate, what data they touch, and how they measure success.

This piece walks through what proactive PMS looks like in practice, what real-world data sources feed it, and how Smarteeva connects the pipeline end-to-end.

Reactive vs Proactive Post-Market Surveillance

Reactive post-market surveillance starts with a complaint, an MDR submission, or a regulator query. The quality team responds, investigates, and closes out. The pace is set by external events.

Proactive post-market surveillance starts with the data. Signal detection runs continuously across complaints, real-world evidence, device telemetry, and literature.

The quality team sees a trend forming before it crosses a regulatory threshold and acts on it. The difference is operational.

Reactive teams measure their performance in days-to-closure. Proactive teams measure it in days-to-detection. Across the Smarteeva customer base, the median days-to-detection sits 30 to 90 days earlier than the equivalent industry baseline for reactive complaint analysis.

What Counts as Real-World Data in MedTech

Real-world data is the structured and unstructured information about device use that lives outside controlled clinical trials. Under EU MDR, FDA's Real-World Evidence framework, and PMDA's guidance, manufacturers are expected to integrate real-world data into their post-market clinical follow-up and ongoing benefit-risk assessments.

Four data sources consistently produce useful signal in MedTech post-market surveillance.

• Electronic Health Records: Electronic Health Records (EHRs) capture device use in the clinical workflow. EHR data feeds include device implantation records, infusion events, surgical outcomes, and adverse event documentation. Smarteeva ingests EHR data through HL7 FHIR APIs and maps clinical events back to device serial numbers.

• Patient Registries: Disease and device-specific patient registries hold longitudinal outcome data that no single manufacturer can produce internally. Cardiac device registries, orthopedic implant registries, and oncology device registries are the most established. Smarteeva integrations pull structured registry data on a defined cadence and align it with the manufacturer's complaint and MDR records.

• Connected Device Telemetry: Connected medical devices generate continuous performance telemetry: pump flow rates, monitor accuracy, battery health, alarm frequency, and software version distributions. Smarteeva ingests device telemetry directly from the device management platform and runs anomaly detection across the population. Telemetry-based signal detection often surfaces emerging failure modes weeks before the first formal complaint arrives.

• Field Service and Customer Support Data: Field service technician notes and customer support tickets contain early signals that often precede formal complaints. Smarteeva extracts structured data from field service records and customer support interactions using the same AI agents that handle complaint intake. The extracted signals feed the same signal detection pipeline as the complaint data.

‍

How Smarteeva Connects and Analyses Real-World Data

Real-world data is only useful if the platform can ingest it at scale, normalize it across sources, and detect signals across the connected dataset. Three Smarteeva capabilities make this possible.

• API-Based Data Ingestion - Smarteeva connects to EHR systems, registries, device telemetry platforms, and field service tools through structured APIs. New data sources can be added without engineering tickets. Every ingested record carries a source attribution, ingestion timestamp, and validation status.

• Signal Detection Across the Device Population - Signal detection runs continuously across complaints, MDRs, real-world data, and connected device telemetry. The detection model surfaces statistical anomalies, emerging failure modes, and device-population trends that human analysts would not catch reading complaints one at a time. Detection thresholds are configurable per device family and per regulatory jurisdiction.

• Predictive Risk Indicators - Smarteeva applies predictive models to the connected dataset to surface risk indicators before they become reportable events. The model identifies devices, lots, and use settings that show elevated risk and flags them to the quality team for investigation. Every prediction comes with the underlying evidence visible to the reviewer.

‍

From Reactive to Proactive: Customer Outcomes

A leading insulin pump manufacturer running connected PMS on Smarteeva cut investigation cycles from 12 days to 3 and reduced complaint research time by 60%. Across the Smarteeva customer base, complaint resolution runs 70% faster than the industry baseline.

The operational shift is not about more data. It is about connecting the data sources that are already producing signal and giving the quality team continuous visibility across the device population.

100% retention. 4 in 5 customers expand within 12 months. Purpose-built for post-market surveillance, AI-powered.

See proactive PMS in action on your own data. Book a 30-minute demonstration

‍

‍Frequently Asked Questions

What is the difference between real-world data and real-world evidence?

Real-world data (RWD) is the underlying data from EHRs, registries, telemetry, and other sources. Real-world evidence (RWE) is the clinical evidence derived from analysing RWD. FDA's RWE framework treats them as related but distinct categories, and Smarteeva supports the full pipeline from RWD ingestion through RWE reporting.

How does Smarteeva ingest real-world data without breaking HIPAA or GDPR?

Smarteeva runs on Salesforce with enterprise-grade encryption, role-based access controls, and audit logging. Real-world data ingestion follows HIPAA Business Associate Agreement requirements in the US and GDPR data processing requirements in the EU. Patient identifiers are tokenized at the ingestion layer where applicable.

How quickly does signal detection surface a new trend?

Signal detection runs continuously. New trends surface as soon as the data crosses a statistical threshold defined in the signal detection model. Most customers see signals 30 to 90 days earlier than they did running reactive complaint analysis.

Does Smarteeva support FDA's Real-World Evidence framework for post-market reporting?

Yes. Smarteeva produces FDA-formatted RWE submissions including data provenance, methodology documentation, and validation records. The platform supports the FDA RWE framework for both 21st Century Cures Act submissions and ongoing post-market reporting.

‍

‍